KR20180058716A - 암을 치료하기 위한 병용 요법 - Google Patents

암을 치료하기 위한 병용 요법 Download PDF

Info

Publication number
KR20180058716A
KR20180058716A KR1020187007757A KR20187007757A KR20180058716A KR 20180058716 A KR20180058716 A KR 20180058716A KR 1020187007757 A KR1020187007757 A KR 1020187007757A KR 20187007757 A KR20187007757 A KR 20187007757A KR 20180058716 A KR20180058716 A KR 20180058716A
Authority
KR
South Korea
Prior art keywords
cancer
tumor
agents
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187007757A
Other languages
English (en)
Korean (ko)
Inventor
레자 파티
드로어 벤-애셔
다니엘 아브람손
Original Assignee
레드힐 바이오파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레드힐 바이오파마 엘티디 filed Critical 레드힐 바이오파마 엘티디
Publication of KR20180058716A publication Critical patent/KR20180058716A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187007757A 2015-10-06 2016-10-06 암을 치료하기 위한 병용 요법 Ceased KR20180058716A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237925P 2015-10-06 2015-10-06
US62/237,925 2015-10-06
PCT/IB2016/001526 WO2017060771A2 (en) 2015-10-06 2016-10-06 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
KR20180058716A true KR20180058716A (ko) 2018-06-01

Family

ID=58446480

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187007757A Ceased KR20180058716A (ko) 2015-10-06 2016-10-06 암을 치료하기 위한 병용 요법

Country Status (12)

Country Link
US (4) US9844540B2 (enExample)
EP (1) EP3359255B1 (enExample)
JP (1) JP6963545B2 (enExample)
KR (1) KR20180058716A (enExample)
CN (1) CN108136207A (enExample)
AU (1) AU2016336133B2 (enExample)
BR (1) BR112018003232A2 (enExample)
CA (1) CA2997671A1 (enExample)
HK (1) HK1259342A1 (enExample)
MX (1) MX382754B (enExample)
RU (1) RU2727474C2 (enExample)
WO (1) WO2017060771A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US20190134219A1 (en) * 2017-09-15 2019-05-09 Ampersand Biopharmaceuticals, Inc. Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases
CA3126818A1 (en) * 2019-01-16 2020-07-23 Apogee Biotechnology Corporation Combination of a sk2 inhibitor and an inhibitor of a checkpoint pathway, uses and pharmaceutical compositions therof
WO2020154716A1 (en) * 2019-01-26 2020-07-30 University Of Rochester Compositions and methods for treating prostate cancer
US11052073B1 (en) 2020-03-10 2021-07-06 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
BR9912327B1 (pt) * 1998-07-20 2013-11-12 Inibidores da uroquinase
AUPR644301A0 (en) * 2001-07-17 2001-08-09 Unisearch Limited Method and composition for treatment of cancer
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US20060142304A1 (en) 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
US20060270631A1 (en) 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
MX2007015863A (es) * 2005-06-17 2008-04-02 Apogee Biotechnology Corp Inhibidores de esfingosina cinasa.
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
EP3560497A1 (en) * 2012-08-30 2019-10-30 The Texas A&M University System Compositions and methods for drug-sensitization or inhibition of a cancer cell
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication

Also Published As

Publication number Publication date
JP2018533560A (ja) 2018-11-15
EP3359255B1 (en) 2025-12-24
US10946000B2 (en) 2021-03-16
US10463654B2 (en) 2019-11-05
EP3359255A4 (en) 2019-06-12
MX2018004309A (es) 2018-05-22
EP3359255A2 (en) 2018-08-15
RU2727474C2 (ru) 2020-07-21
US20200113881A1 (en) 2020-04-16
WO2017060771A2 (en) 2017-04-13
RU2018109902A (ru) 2019-11-07
US9844540B2 (en) 2017-12-19
AU2016336133A1 (en) 2018-03-15
BR112018003232A2 (pt) 2018-09-25
WO2017060771A3 (en) 2017-07-06
US11633385B2 (en) 2023-04-25
RU2018109902A3 (enExample) 2020-03-05
JP6963545B2 (ja) 2021-11-10
US20170095460A1 (en) 2017-04-06
US20210128538A1 (en) 2021-05-06
HK1259342A1 (zh) 2019-11-29
CA2997671A1 (en) 2017-04-13
CN108136207A (zh) 2018-06-08
AU2016336133B2 (en) 2021-02-25
MX382754B (es) 2025-03-13
US20180125831A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
JP6963545B2 (ja) 癌を治療するための併用療法
KR102356433B1 (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
KR101707669B1 (ko) 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
AU2016213972A1 (en) Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
KR20140025374A (ko) 3-(5-아미노-2-메틸-4-옥소-4ｈ-퀴나졸린-3-일)-피페리딘-2,6-디온을 사용하는 암의 치료 방법
JP2013107903A (ja) 化学療法の強化方法
JP2020512377A (ja) がんを処置および／または防止するための組成物
ES2898681T3 (es) Amplificadores del canibalismo celular para la utilización para sensibilizar tumores a la terapia de radiación
JP2019514864A (ja) 肝癌の治療方法
US20240067604A1 (en) Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer
JP7571053B2 (ja) 軟部肉腫の併用療法用キノリン誘導体
JP7822619B2 (ja) 胆管癌の処置のためのパノビノスタットを含む併用療法
CN109985030B (zh) 醌式查尔酮化合物在制备抗肿瘤药物中的应用
CN115969975A (zh) Phgdh抑制剂在预防和/或治疗结直肠癌转移中的应用
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
EP3854411A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
CN121925259A (zh) 血液癌的新型联合疗法
JP2022543021A (ja) がんを処置する方法及び使用
UA110964C2 (uk) Застосування 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону для лікування раку

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000